The S1 Dataset provides demographic, clinical, and biomarker data for 90 participants (60 Long COVID patients and 30 controls).

It includes: demographics: Age, sex, BMI, education year, smoking status, marital status, urban/rural residence, and employment status. Acute Phase Indicators: Peak body temperature (PBT), lowest SpO2, and duration of the acute infectious phase (days). Symptom Scales: Hamilton Depression Rating Scale (HAMD), Hamilton Anxiety Rating Scale (HAMA), and Fibro-Fatigue (FF) scale scores. Laboratory Biomarkers: CRP, PGE2, PAI1, glucose, insulin, HOMA2IR, HOMA2%S, NSE, S100B, galanin, GALR1, and IGF-1. This dataset underpins the study’s analysis of the associations between biomarkers, neuropsychiatric symptoms, and chronic fatigue syndrome in Long COVID patients. BMI, body mass index; PBT, peak body temperature; HAMA, Hamilton Anxiety Rating Scale; HAMD, Hamilton Depression Rating Scale; FF, Fibro-Fatigue scale; SpO2, oxygen saturation; Vaccination A, PF, S, vaccination with AstraZeneca, Pfizer, or Sinopharm; CRP, C-reactive protein; S100B, calcium-binding protein B; PAI1, plasminogen activator inhibitor-1; HOMA2IR, Homeostasis Model Assessment 2 insulin resistance index; HOMA2%S, HOMA insulin sensitivity percentage; NSE, neuron-specific enolase; IGF-1, Insulin-Like Growth Factor-I; PGE2, prostaglandin E2; GALR1, galanin receptor 1. For more information, refer to the explanatory sections in Tables 1 and 2 of the manuscript. (SAV)